**DOCKET NO.: ADOL-0497** 

## **PATENT**

#17/D DE: P/KD 2-4-03



REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 C.F.R. § 1.116

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kruse, et al.

Confirmation No.: 4357

Serial No.: 09/769,450

**Group Art Unit: 1617** 

Filing Date: January 26, 2001

Examiner: Wang, Shengjun

For: Kappa Agonist Compounds, Pharmaceutical Formulations And Method Of

**Prevention And Treatment Of Pruritus Therewith** 

EXPRESS MAIL LABEL NO: EV 160092470 US DATE OF DEPOSIT: January 23, 2003

Box AF Assistant Commissioner for Patents Washington DC 20231

Sir:

## REPLY UNDER 37 C.F.R. § 1.116 TO OFFICE ACTION DATED JULY 23, 2002

In response to the Final Official Action dated July 23, 2002, applicants respectfully request that the application be amended, without prejudice, as follows.

## In the Claims

Ø

25. (Twice amended) A method of treating or preventing pruritus in a mammal in need of such prevention or treatment, said method comprising administering to said mammal an arylacetamide non-peptide kappa opiate receptor agonist, or a pharmaceutically acceptable salt thereof, that is devoid of central nervous system effects, in a pharmaceutically acceptable carrier.